Evidence map›Paper›PMID 31511499›Full record

ArticleCell death & disease2019

Fibroblast growth factor 21 Ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2/AMPKα signaling pathway.

Lei Ying, Na Li, Zhengyue He, Xueqin Zeng, Yan Nan, Jiantong Chen, Peipei Miao, Yunyun Ying, Wei Lin, Xinyu Zhao and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. EndothelialCurrent diabetes reviews · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Lei YingDepartment of Pathophysiology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Na LiDepartment of Pathophysiology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Zhengyue HeDepartment of Pathophysiology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Xueqin ZengDepartment of Pathophysiology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Yan NanThe Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Jiantong ChenDepartment of Pathophysiology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Peipei MiaoDepartment of Pathophysiology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Yunyun YingDepartment of Pathophysiology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Wei LinSchool of Pharmaceutical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Xinyu ZhaoSchool of Pharmaceutical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Lu LuThe Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Mengke ChenThe First Affiliated Hospital & School of the First Clinical Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Wei CenThe First Affiliated Hospital & School of the First Clinical Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Tonglin GuoSchool of Ophthalmology and Optometry, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China.
Xiaokun LiSchool of Pharmaceutical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China. lixk1964@163.com.
Zhifeng HuangSchool of Pharmaceutical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China. cpu_son@163.com.
Yang WangDepartment of Pathophysiology, School of Basic Medical Sciences, Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China. wangydh995@163.com.
Wenzhou Medical University · CNFirst Affiliated Hospital of Wenzhou Medical University · CNSecond Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial dysfunction initiates and exacerbates hypertension, atherosclerosis and other cardiovascular complications in diabetic mellitus. FGF21 is a hormone that mediates a number of beneficial effects relevant to metabolic disorders and their associated complications. Nevertheless, it remains unclear as to whether FGF21 ameliorates endothelial dysfunction. Therefore, we investigated the effect of FGF21 on endothelial function in both type 1 and type 2 diabetes. We found that FGF21 reduced hyperglycemia and ameliorated insulin resistance in type 2 diabetic mice, an effect that was totally lost in type 1 diabetic mice. However, FGF21 activated AMPKα, suppressing oxidative stress and enhancing endothelium-dependent vasorelaxation of aorta in both types, suggesting a mechanism that is independent of its glucose-lowering and insulin-sensitizing effects. In vitro, we identified a direct action of FGF21 on endothelial cells of the aorta, in which it bounds to FGF receptors to alleviate impaired endothelial function challenged with high glucose. Furthermore, the CaMKK2-AMPKα signaling pathway was activated to suppress oxidative stress. Apart from its anti-oxidative capacity, FGF21 activated eNOS to dilate the aorta via CaMKK2/AMPKα activation. Our data suggest expanded potential uses of FGF21 for the treatment of vascular diseases in diabetes.

Indexed as

AMP-Activated Protein KinasesAnimalsAortaCalcium-Calmodulin-Dependent Protein Kinase KinaseDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic AngiopathiesEndothelial CellsEndothelium, VascularFibroblast Growth FactorsHumansHuman Umbilical Vein Endothelial CellsHyperglycemiaInsulin ResistanceMaleAMP-Activated Protein KinasesCalcium-Calmodulin-Dependent Protein Kinase KinaseCamkk2 protein, mouseFGF21 protein, humanFibroblast Growth FactorsNitric Oxide Synthase Type IIINos3 protein, mouseRecombinant Proteins

Identifiers

PMID31511499
PMCPMC6739326
OpenAlexW2973113192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.